Building on these advances, H103, a type-2 recombinant that overexpresses heat-shock protein 70, was developed to boost both direct tumor lysis and HSP70-driven immune responses against primary and metastatic disease [11]. This evidence concerns the gene HSPA1A and neoplasm.